Date and Time: Monday, March 25, 2024 - 12:00 PM - 1:00 PM EDT
Faculty: Savitri Krishnamurthy, MD, The University of Texas MD Anderson Cancer Center
Course Description
In this live session titled, “Actionable next-generation sequencing panel-based biomarkers in breast cancer: exploring the value of identifying patients with PIK3CA, AKT1, and PTEN alterations”, we will discuss the role of PIK3CA, AKT1, and PTEN genes and the importance of identifying actionable alterations within them in patients with advanced HR+/HER2- breast cancer.
We will cover the nature and prevalence of PIK3CA, AKT1, and PTEN alterations and the use of next-generation sequencing (NGS) panel testing to detect these biomarkers. Additionally, real-world case studies will be shared to demonstrate some key NGS considerations in clinical practice.
Ultimately, this session aims to educate on the actionable biomarkers of PIK3CA, AKT1, and PTEN in breast cancer and help pathologists become advocates of NGS testing for patients with advanced breast cancer.
Privacy Notice
The webinar is possible through AstraZeneca Precision Medicine. This
content is not available for continuing medical education. If you
continue to register, you are acknowledging that your information will
be shared with the company, including your name, degrees, institution,
NPI number, mailing address, email address, and phone number. USCAP has
no control over the use of this information.
The information presented represents the opinion of the presenters and
is not necessarily the view of USCAP. USCAP does not endorse the
products or services. The webinar is possible through AstraZeneca
Precision Medicine. This activity is not available for CME.